SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CTEC: Cholestech any other investors?

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Lane3 who wrote (681)8/18/1999 11:57:00 AM
From: mike boyajian  Read Replies (1) of 710
 
The problem is that CTEC needs a big brother like Parke-Davis to underwrite this whole new business model (at least for the pharmacists). Normal every day "Joes and Janes" are not going to pay to have their lipids checked. So either a big brother like Parke-Davis will have to hold their hands (customers, pharmacists, CTEC) or they have to solve the third party payer situation (insurance companies).

The preferable solution at least in my mind is to have Parke-Davis step in and run the show with their deep pockets. Project IMPACT results (due out February 2000) will illustrate that Parke-Davis is losing $Millions in Lipitor revenue because some 60% of patients stop taking the medication after one year. In order to get patients to do the testing it must be offered free or at a very low price (cost absorbed by Parke-Davis).

Mike
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext